Analyzing the MARIPOSA-2 Trial Data’s Impact on Clinical Practice

Opinion
Video

Cara Chang, PharmD, BCOP, provides a comprehensive analysis of the MARIPOSA-2 trial, evaluating the various study arms and interpreting the practice-changing data presented.

  1. The MARIPOSA-2 trial, a recent publication from January, assessed patients with Ex19del or Ex21 L858R mutations who had progressed on osimertinib. It compared three treatment arms: amivantamab plus lazertinib plus chemotherapy, amivantamab plus chemotherapy (without lazertinib), and chemotherapy alone. What are the significant findings of this study, and what are the key insights that could influence clinical practice?
  2. When it comes to patients with S768I, L861Q, and/or G719X mutations, how does their treatment approach differ from (or is similar to) those observed in the FLAURA2 and MARIPOSA / MARIPOSA-2 studies?
Recent Videos
Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, an expert on RSV
Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, an expert on RSV
Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, an expert on RSV
Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, an expert on RSV
1 KOL is featured in this program
Carrie Koenigsfeld, PharmD, FAPhA, an expert on RSV vaccination
Carrie Koenigsfeld, PharmD, FAPhA, an expert on RSV vaccination
1 KOL is featured in this program
1 KOL is featured in this program